Bioavailability Study of Epinephrine via Auto-Injector Versus Intramuscular Injection in Healthy Adults with Type 1 Allergic Reactions, Including Anaphylaxis

The primary objective of this study is to evaluate the **bioavailability** of **epinephrine** following a single dose administered via an emergency response auto-injector compared to an epinephrine injection into the muscle using a syringe in healthy adults. This is clinically relevant as it aims to determine the efficacy and absorption rate of epinephrine, which is critical in the management of **allergic reactions (Type 1)**, including anaphylaxis, idiopathic anaphylaxis, or exercise-induced anaphylaxis. Understanding the bioavailability of epinephrine in these emergency situations can inform best practices for treatment and improve patient outcomes.

The clinical trial involves participants diagnosed with **allergic reactions** (Type 1), including anaphylaxis, idiopathic anaphylaxis, or exercise-induced anaphylaxis. The study population includes both male and female subjects, with an age range of 18 to 64 years. The trial population was selected to include a vulnerable population, although specific selection criteria have not been disclosed. The sponsor has not provided information regarding the total number of participants. Lifestyle considerations such as diet, physical activity, or habits have not been specified. The study aims to gather data from a diverse group of individuals within the specified age range, ensuring a comprehensive understanding of the condition across different demographics.

The clinical trial is designed to evaluate the **bioavailability** of epinephrine following a single dose of an emergency response auto-injector compared to epinephrine injection into muscle via syringe in healthy adults. This study is a Phase 3 trial, which is randomized, double-blind, and controlled to ensure the reliability and validity of the results. The trial is expected to commence recruitment on January 6, 2025, and conclude by February 14, 2025, with the overall duration of the trial being approximately six weeks.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for inclusion. Following the screening, participants will be randomly assigned to receive either the auto-injector or the syringe method of epinephrine administration. Subsequent follow-up visits will be scheduled to monitor the participants' response to the treatment, assess any adverse effects, and collect data on the primary and secondary endpoints of the study. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data for analysis.

The expected length of participant involvement is approximately six weeks, encompassing the initial screening, treatment administration, and follow-up assessments. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study protocols, or withdrawal of consent by the participant. The study aims to provide valuable insights into the efficacy and safety of the emergency response auto-injector compared to traditional syringe administration in managing **allergic reactions** such as anaphylaxis.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. Consequently, the trial documentation lacks comprehensive information on the treatment protocols and methodologies employed in the study.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on January 6, 2025, with an estimated end date of February 14, 2025. The efficacy assessment will be conducted through a series of predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the treatment's impact on the specified medical condition, utilizing appropriate clinical methodologies and tools as per standard Phase 3 trial protocols. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy outcomes.